Dr. Lisa Egbuonu-Davis was elected to our Board in March 2023. She is a member of our Compliance Committee and Governance Committee. Since 2021, Dr. Egbuonu-Davis has served on the Board of Directors of Omega Healthcare Investors, Inc. (NYSE: OHI), a real estate investment trust focused on healthcare-related real estate properties. She is a member of that company’s Nominating and Corporate Governance Committee. Since July 2023, she has served on the Board of Directors of Phreesia, Inc. (NYSE: PHR), a provider of software solutions that improve the operational and financial performance of healthcare organizations. From 2019 to July 2023, Dr. Egbuonu-Davis served as Vice President, Medical Innovations for DH Diagnostics, LLC, an affiliate of Danaher Corporation (NYSE:DHR), where she provided medical advice to influence research, partnership and investment strategy across Danaher’s diagnostic platform businesses. During that period, she served at various times as Interim Chief Medical Officer of Leica Biosystems and Beckman Coulter Diagnostics, both affiliates of Danaher Corporation. From 2015 to 2019, she served as Vice President, Global Patient Centered Outcomes and Solutions at Sanofi, Inc. (NASDAQ:SNY). At Sanofi, Dr. Egbuonu-Davis created patient programs, services and tools to enhance adherence and health outcomes in patients with chronic conditions. Prior to Sanofi, Dr. Egbuonu-Davis co-founded and served as director for ROI Squared, LLC, a privately-held life science company focused on diagnostic medical devices, and served as managing director for LED Enterprise, LLC, where she advised biopharmaceutical companies and trade associations on health care reform, technology assessment, quality metrics and incentives and implications for research and services. She also served in senior advisor roles for Avalere Health and Booz Allen Hamilton. She also previously served for 13 years in various roles at Pfizer, Inc. (NYSE:PFE), where she led clinical and outcomes research departments, supported product value assessments in support of reimbursement and adoption and influenced product investment and development decisions. She has served on the Johns Hopkins Medicine Board of Trustees since 2021 and the National Advisory Council for the Johns Hopkins University School of Education since 2007.